Epogen

Anemia Drugs May Speed Tumor Growth in Some Cancer Patients

... American Society of Clinical Oncology annual meeting in Chicago. Recent controversy over erythropoiesis-stimulating agents (ESAs) such as Procrit, epogen and Aranesp has centered around whether the blood-boosting drugs should be withdrawn from the market because of troubling side effects. In March, a...

FDA Panel Supports Anemia Drugs for Cancer Patients

...ferers should steer clear of the medications. According to the Wall Street Journal , the panel voted 13-1 for letting Amgen Inc. continue selling epogen and Aranesp and Johnson & Johnson continue selling Procrit. But the panel voted 11-2 to recommend against the drugs' use for cancer patients who a...

FDA Panel Weighs Safety of Anemia Drugs for Cancer Patients

...ccording to FDA briefing documents filed this week, there are now a total of eight clinical trials that suggest these widely used medications, sold as epogen and Aranesp by Amgen Inc. and as Procrit by Johnson&Johnson, actually speed the growth of tumors and shorten the lives of cancer victims. Known as...

FDA Reports New Risks Posed by Anemia Drugs

...dministration officials said in a prepared statement. On Nov. 8, the FDA approved new "black box" warnings on labels of the three ESAs -- Aranesp, epogen and Procrit. The warnings detailed the dangers to patients with cancer and patients with chronic kidney failure. Those dangers include heart attack, s...

Drug Safety, Tainted Food Among Year's Top Health Stories

...re cases, the drugs might even cause harm. Also this fall, the FDA added black-box heart-risk warnings to blockbuster anemia drugs such as Procrit, epogen and Aranesp. The agency found little evidence to back up drug makers' claims that the medicines can ease the fatigue of cancer patients and other user...

National Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs)

...s to visit http://www.npaf.org to view the FDA Public Health Announcement, FDA Questions and Answers and the full text of the new FDA labels for the epogen and Aranesp and to contact our specialized case managers via 1-800-532-5274 to learn more. ...

FDA Issues New Warnings for Anemia Drugs

... to treat certain types of anemia. The warnings cover the drugs Aranesp, epogen and Procrit, and detail their dangers to patients with cancer and patients ...c kidney failure and anemia caused by chemotherapy in some cancer patients. epogen and Procrit are also used in some anemic patients who are undergoing surger...

Controversial Anemia Drug Doesn't Cut Need for Transfusions

...the need for blood transfusions among critically ill patients, but it may reduce mortality in trauma patients. The drug, epoetin alfa (brand names epogen and Procrit) has been under regulatory scrutiny because of potentially dangerous side effects. "Unlike prior studies, this trial found that we didn...

Anemia Drug Overused and Could Hasten Death in Some, Say Experts

...g each year, said Craig Tendler, a physician and vice president of Ortho Biotech, which sells it under the Procrit name. The two other brand names are epogen and Aranesp, a modified form of erythropoietin. A high FDA official said his office will look into how another section of the agency approved adv...

Popular Anemia Drug Dodges The Dagger

...hances of death in// lung cancer patients who are undergoing chemotherapy. This has resulted in sales of the drug shooting up. Aranesp, along with epogen from Amgen and Procrit from Johnson & Johnson, are used by nearly a million Americans a year, mainly to treat anemia from kidney disease or cancer che...

Epogen in Biological Technology

Entry of Biogenerics and Decreasing Use of Amgen's Epogen and Johnson & Johnson's Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016

Upheaval is Forecasted for the Markets of Five Chemotherapy Side Effect Indications, According to a New Report from Decision Resources WALTHAM, Mass., Oct. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues...

Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55

...in the average net sales price and lighter year end customer demand, partially offset by an increase in patient population growth. For the full year, epogen sales were $2,456 million in 2008 versus $2,489 million in 2007, a 1 percent decrease. This decrease in sales is principally due to a slight decline ...

BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...PO hypo-responders, and increased focus on patients' iron status. The commercialization of new ESAs could also alter market dynamics in which Amgen's epogen currently leads the dialysis market and Ortho Biotech's Procrit and Amgen's Aranesp virtually split the CKD market. Even though the perceived need fo...

BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

..., and dose reductions) and more than two-thirds do not anticipate making any additional changes to their use of ESAs in CKD or dialysis. While Amgen's epogen continues to dominate the dialysis market, there did seem to be some brand shifting between Amgen's Aranesp and Ortho Biotech's Procrit in CKD. Nephro...

BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

... ESA use has decreased specifically due to managed care policies. While there have been no significant changes in market share year over year (Amgen's epogen remains the market leader in dialysis and Ortho Biotech's Procrit and Amgen's Aranesp continue to battle for market leader position in CKD), there are...

Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board

...ce in the pharmaceutical and biotechnology industries. Most notably he was responsible at Amgen Europe for the commercial roll-out of Neupogen (R) and epogen (R), the two first biotech blockbuster products. Subsequently he served as an executive at Genzyme Europe, overseeing the commercialization of Genzyme...

BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...lected in their lower hemoglobin targets. More than three quarters of the nephrologists state that they do not anticipate any further changes. Amgen's epogen continues its position as market share leader in dialysis while Aranesp and Procrit continue to battle for market leader position in pre-dialysis. I...

Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers

...ccording to the new special report entitled Biogenerics 2007- 2016: Physician and Payer Acceptance Fuels Brand Erosion, Amgen products such as Enbrel, epogen and Neupogen will be eroded by biogeneric sales in both the United States and Europe. In fact, on August 31, 2007, European regulators approved Sandoz...

The Coming of Biotech Generic Pharmaceuticals

...Of the top 10 biotech drugs, eight already have generic competition either in the works or on the market. Most affected will be Amgen as not only does epogen and Neupogen go off patent in the next few years but Amgen is the discoverer of J&Js Procrit, which licensed the product from Amgen (which will also b...

Biotech industry reaches midpoint in 50-year maturation cycle

...e (late 1980s to late 1990s): A few new discoveries became products using the above methodologies. Good examples of this include Amgen growth factors epogen and Neupogen as well as Genentech?s recombinant insulin and human growth hormone. Third Decade (late 1990s to 2010): A flood of innovative products ...